Genentech, Inc. is running a clinical trial to test a drug called Emicizumab to treat hemophilia A. This Phase IV, multicenter study will evaluate whether participants with Hemophilia A and inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures without prophylactic bypassing agents (BPA).
The drug is Emicizumab.
| Study Type : |
Interventional (Clinical Trial) |
| Estimated Enrollment : |
30 participants |
| Intervention Model: |
Single Group Assignment |
| Masking: |
None (Open Label) |
| Primary Purpose: |
Treatment |
| Official Title: |
A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures |
| Actual Study Start Date : |
April 30, 2018 |
| Estimated Primary Completion Date : |
June 28, 2019 |
| Estimated Study Completion Date : |
June 28, 2019 |
Contacts
| Contact: Reference Study ID: ML39791 www.roche.com/about_roche/roche_worldwide.htm |
888-662-6728 (U.S. Only) |
global-roche-genentech-trials@gene.com |
NCT Number
For enrollment please visit www.clinicaltrials.gov.
